Skip to main content

Advertisement

Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer

Fig. 7

Immune monitoring, plasma level and IFN-γ ELISpot during and after therapeutic chemo-immunotherapy. a Flow cytometric immune monitoring of blood leukocytes was done routinely during vaccination and at the experimental endpoint. Given are the percentage numbers of positive cells ± SD resulting from 20,000 events measured on a flow cytometer. *** p < 0.001 vs. control; T-test. b Immunophenotyping of splenocytes from mice of all groups. Given are the percentage numbers of positive cells ± SD resulting from 20,000 events measured on a flow cytometer. * p < 0.05 vs. control; one-way ANOVA (Holm Sidak method). c Plasma cytokine levels of IL-10, IL-13, MCP-1, RANTES, and Eotaxin from mice with therapeutic chemo-immunotherapy and controls. Plasma samples were collected at the experimental endpoint and cytokine levels were determined as described in material and methods. d Number of IFN-γ secreting cells after over-night incubation of splenocytes (=effector cells) and tumor target cells (MLH1−/− 7450 T1 M1, MLH1−/− 328, MLH1−/− 1351, and YAC-1). Lymphocytes were isolated from mice of all groups showing increased reactivity post treatment

Back to article page